-
Endo ends axomadol collaboration with Grunenthal
CHADDS FORD, Pa. — Endo Pharmaceuticals has ended its research program and collaboration with Grunenthal.
The announcement comes shortly after the companies revealed their mid-stage clinical trial results for axomadol — designed to treat chronic low back pain — did not meet the predetermined endpoint.
Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.